Arcutis Biotherapeutics (ARQT) Set to Release Quarterly Earnings on Wednesday

Arcutis Biotherapeutics (NASDAQ:ARQT) will likely be releasing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of $0.18 per share and revenue of $142.59 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.05. The business had revenue of $129.86 million during the quarter, compared to analysts’ expectations of $118.85 million. Arcutis Biotherapeutics had a net margin of 6.15% and a return on equity of 15.05%. On average, analysts expect Arcutis Biotherapeutics to post $0.43 EPS for the current fiscal year and $1.06 EPS for the next fiscal year.

Arcutis Biotherapeutics Stock Performance

NASDAQ:ARQT opened at $32.07 on Monday. Arcutis Biotherapeutics has a 52 week low of $19.30 and a 52 week high of $33.30. The firm has a 50-day moving average price of $26.66 and a two-hundred day moving average price of $25.28. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.67 and a current ratio of 2.92. The firm has a market cap of $4.03 billion, a price-to-earnings ratio of 152.72 and a beta of 1.66.

Insiders Place Their Bets

In other Arcutis Biotherapeutics news, insider Masaru Matsuda sold 3,674 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $25.00, for a total value of $91,850.00. Following the completion of the sale, the insider directly owned 112,508 shares in the company, valued at approximately $2,812,700. This trade represents a 3.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Terrie Curran sold 38,200 shares of the stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $25.03, for a total transaction of $956,146.00. Following the completion of the sale, the director owned 23,526 shares of the company’s stock, valued at approximately $588,855.78. The trade was a 61.89% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 77,393 shares of company stock worth $1,971,944. 9.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $39.00 price target on shares of Arcutis Biotherapeutics in a report on Thursday, October 8th. Weiss Ratings upgraded shares of Arcutis Biotherapeutics from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday. Guggenheim boosted their price objective on Arcutis Biotherapeutics from $38.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, October 19th. Cantor Fitzgerald assumed coverage on shares of Arcutis Biotherapeutics in a report on Thursday, October 15th. They issued an “overweight” rating and a $48.00 target price on the stock. Finally, Wall Street Zen downgraded Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 10th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $39.12.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.